Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)

This study has been completed.
Sponsor:
Collaborators:
Regeneron Pharmaceuticals
NSABP Foundation Inc
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00561470
First received: November 20, 2007
Last updated: September 27, 2012
Last verified: March 2012
Results First Received: August 17, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Conditions: Colorectal Neoplasms
Neoplasm Metastasis
Interventions: Drug: Placebo
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between 19 November 2007 and 16 March 2010, 614 participants were randomized to the placebo arm and 612 participants were randomized to the aflibercept arm.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo/FOLFIRI Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks
Aflibercept/FOLFIRI Participants with Metastatic Colorectal Cancer administered 4 mg/kg of Aflibercept, followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks

Participant Flow:   Overall Study
    Placebo/FOLFIRI   Aflibercept/FOLFIRI
STARTED   614   612 
TREATED   609   607 
SAFETY POPULATION   605 [1]   611 [2] 
ONGOING TREATMENT   11 [3]   14 [3] 
COMPLETED   0 [4]   0 [4] 
NOT COMPLETED   614   612 
Adverse Event                74                163 
Disease progression                437                305 
poor compliance to protocol                4                4 
Lost to Follow-up                2                0 
Physician Decision                21                20 
Consent Withdrawn                2                6 
Subject request                43                77 
Metastatic surgery                10                12 
Unauthorized procedure                3                1 
Randomized but not treated                5                5 
Missed visit window                1                4 
Planning surgery                1                1 
Ongoing Treatment                11                14 
[1] Treated participants excluding 4 who received at least 1 dose of Aflibercept
[2] Treated participants including 4 from Placebo/FOLFIRI who received at least 1 dose of Aflibercept
[3] Participants continuing treatment on the cutoff date of the final analysis
[4] Participants met treatment discontinuation criteria or were ongoing treatment on the cutoff date



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo/Folfiri Participants with Metastatic Colorectal Cancer administered Placebo and FOLFIRI (Irinotecan, 5- Fluorouracil, and Leucovorin)
Aflibercept/Folfiri Participants with Metastatic Colorectal Cancer administered 4 mg/kg of Aflibercept and FOLFIRI (Irinotecan, 5- Fluorouracil, and Leucovorin)
Total Total of all reporting groups

Baseline Measures
   Placebo/Folfiri   Aflibercept/Folfiri   Total 
Overall Participants Analyzed 
[Units: Participants]
 614   612   1226 
Age 
[Units: Years]
Mean (Standard Deviation)
 60.2  (10.8)   59.5  (10.5)   59.8  (10.7) 
Age, Customized 
[Units: Participants]
     
<65 years   376   407   783 
>=65 but <75 years   199   172   371 
>=75 years   39   33   72 
Gender, Customized 
[Units: Participants]
     
Male   353   365   718 
Female   261   247   508 
Race/Ethnicity, Customized 
[Units: Participants]
     
Caucasian/White   523   548   1071 
Black   27   16   43 
Asian/Oriental   51   35   86 
Other   13   13   26 
Region of Enrollment 
[Units: Participants]
     
ARGENTINA   4   2   6 
AUSTRALIA   42   54   96 
AUSTRIA   3   4   7 
BELGIUM   37   45   82 
BRAZIL   21   27   48 
CHILE   31   33   64 
CZECH REPUBLIC   30   47   77 
DENMARK   9   6   15 
ESTONIA   7   3   10 
FRANCE   1   1   2 
GERMANY   23   12   35 
GREECE   9   10   19 
ITALY   26   23   49 
KOREA, REPUBLIC OF   39   26   65 
NETHERLANDS   20   14   34 
NEW ZEALAND   13   7   20 
NORWAY   14   19   33 
POLAND   24   32   56 
PUERTO RICO   4   2   6 
ROMANIA   16   16   32 
RUSSIAN FEDERATION   35   40   75 
SOUTH AFRICA   36   31   67 
SPAIN   27   28   55 
SWEDEN   10   4   14 
TURKEY   4   2   6 
UKRAINE   11   11   22 
UNITED KINGDOM   47   52   99 
UNITED STATES   71   61   132 
Eastern Cooperative Oncology Group (ECOG) performance status score [1] 
[Units: Participants]
     
Participants with ECOG Score = 0   350   349   699 
Participants with ECOG Score = 1   250   250   500 
Participants with ECOG Score = 2   14   13   27 
[1] The ECOG score assesses how the disease affects a participant's daily living abilities. It ranges from 0-5, with 0 being the best and 5 being the worst outcome. "0" reflects a fully active participant, able to carry on all pre-disease performance without restriction. "1" reflects a participant restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. "2" reflects an ambulatory participant, who is up and about more than 50% of waking hours, and capable of all self-care but unable to carry out any work activities.
Prior Bevacizumab [1] 
[Units: Participants]
     
Yes   187   186   373 
No   427   426   853 
[1] Number of participants randomized in the prior bevacizumab stratum as per the interactive voice response system (IVRS).


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival (OS)   [ Time Frame: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years) ]

2.  Secondary:   Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)   [ Time Frame: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months) ]

3.  Secondary:   Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria   [ Time Frame: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months) ]

4.  Secondary:   Number of Participants With Adverse Events (AE)   [ Time Frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized ]

5.  Secondary:   Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay   [ Time Frame: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame From treatment initiation to 7 February, 2011
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5  

Reporting Groups
  Description
Placebo/FOLFIRI Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks
Aflibercept/FOLFIRI Participants with Metastatic Colorectal Cancer administered 4 mg/kg of Aflibercept, followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) every two weeks

Other Adverse Events
    Placebo/FOLFIRI   Aflibercept/FOLFIRI
Total, other (not including serious) adverse events     
# participants affected / at risk   575/605 (95.04%)   599/611 (98.04%) 
Blood and lymphatic system disorders     
Neutropenia * 1     
# participants affected / at risk   202/605 (33.39%)   229/611 (37.48%) 
Gastrointestinal disorders     
Diarrhoea * 1     
# participants affected / at risk   335/605 (55.37%)   411/611 (67.27%) 
Nausea * 1     
# participants affected / at risk   327/605 (54.05%)   322/611 (52.70%) 
Stomatitis * 1     
# participants affected / at risk   199/605 (32.89%)   304/611 (49.75%) 
Vomiting * 1     
# participants affected / at risk   199/605 (32.89%)   194/611 (31.75%) 
Abdominal pain * 1     
# participants affected / at risk   141/605 (23.31%)   158/611 (25.86%) 
Constipation * 1     
# participants affected / at risk   146/605 (24.13%)   135/611 (22.09%) 
Abdominal pain upper * 1     
# participants affected / at risk   46/605 (7.60%)   63/611 (10.31%) 
Dyspepsia * 1     
# participants affected / at risk   56/605 (9.26%)   50/611 (8.18%) 
Haemorrhoids * 1     
# participants affected / at risk   13/605 (2.15%)   34/611 (5.56%) 
Proctalgia * 1     
# participants affected / at risk   11/605 (1.82%)   32/611 (5.24%) 
General disorders     
Fatigue * 1     
# participants affected / at risk   234/605 (38.68%)   292/611 (47.79%) 
Asthenia * 1     
# participants affected / at risk   77/605 (12.73%)   109/611 (17.84%) 
Pyrexia * 1     
# participants affected / at risk   73/605 (12.07%)   77/611 (12.60%) 
Oedema peripheral * 1     
# participants affected / at risk   42/605 (6.94%)   52/611 (8.51%) 
Infections and infestations     
Urinary tract infection * 1     
# participants affected / at risk   35/605 (5.79%)   51/611 (8.35%) 
Investigations     
Weight decreased * 1     
# participants affected / at risk   87/605 (14.38%)   195/611 (31.91%) 
Metabolism and nutrition disorders     
Decreased appetite * 1     
# participants affected / at risk   143/605 (23.64%)   195/611 (31.91%) 
Dehydration * 1     
# participants affected / at risk   12/605 (1.98%)   33/611 (5.40%) 
Musculoskeletal and connective tissue disorders     
Back pain * 1     
# participants affected / at risk   69/605 (11.40%)   72/611 (11.78%) 
Arthralgia * 1     
# participants affected / at risk   40/605 (6.61%)   31/611 (5.07%) 
Pain in extremity * 1     
# participants affected / at risk   33/605 (5.45%)   34/611 (5.56%) 
Nervous system disorders     
Headache * 1     
# participants affected / at risk   53/605 (8.76%)   136/611 (22.26%) 
Dizziness * 1     
# participants affected / at risk   53/605 (8.76%)   36/611 (5.89%) 
Dysgeusia * 1     
# participants affected / at risk   32/605 (5.29%)   42/611 (6.87%) 
Neuropathy peripheral * 1     
# participants affected / at risk   30/605 (4.96%)   34/611 (5.56%) 
Lethargy * 1     
# participants affected / at risk   28/605 (4.63%)   33/611 (5.40%) 
Psychiatric disorders     
Insomnia * 1     
# participants affected / at risk   45/605 (7.44%)   47/611 (7.69%) 
Renal and urinary disorders     
Proteinuria * 1     
# participants affected / at risk   9/605 (1.49%)   63/611 (10.31%) 
Respiratory, thoracic and mediastinal disorders     
Epistaxis * 1     
# participants affected / at risk   45/605 (7.44%)   168/611 (27.50%) 
Dysphonia * 1     
# participants affected / at risk   20/605 (3.31%)   155/611 (25.37%) 
Cough * 1     
# participants affected / at risk   58/605 (9.59%)   67/611 (10.97%) 
Dyspnoea * 1     
# participants affected / at risk   51/605 (8.43%)   69/611 (11.29%) 
Oropharyngeal pain * 1     
# participants affected / at risk   19/605 (3.14%)   45/611 (7.36%) 
Rhinorrhoea * 1     
# participants affected / at risk   11/605 (1.82%)   38/611 (6.22%) 
Skin and subcutaneous tissue disorders     
Alopecia * 1     
# participants affected / at risk   182/605 (30.08%)   164/611 (26.84%) 
Palmar-plantar erythrodysaesthesia syndrome * 1     
# participants affected / at risk   26/605 (4.30%)   67/611 (10.97%) 
Rash * 1     
# participants affected / at risk   35/605 (5.79%)   41/611 (6.71%) 
Skin hyperpigmentation * 1     
# participants affected / at risk   17/605 (2.81%)   50/611 (8.18%) 
Hyperhidrosis * 1     
# participants affected / at risk   33/605 (5.45%)   17/611 (2.78%) 
Vascular disorders     
Hypertension * 1     
# participants affected / at risk   65/605 (10.74%)   250/611 (40.92%) 
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 13.1



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information